The Horizons Tracker

NOVEMBER 29, 2023

“Noting the benefits of diverse experiences in the board room, corporate executives can search beyond the tradition director pedigree (e.g. Moderna, a prominent pharmaceutical and biotechnology firm, adopted an unconventional approach utilizing RNA technology to develop one of the COVID-19 vaccines.

Diversity 96

Diversity Innovation Biotechnology Short-term 96

Harvard Business Review

NOVEMBER 10, 2017

Despite the amount they invest in corporate learning, organizations continue to struggle to connect these programs with the day-to-day work of strategy execution. ” But to enable strategy execution, learning departments need to reorient from what they’re trying to teach to where these things show up in the work.

Skills 11

Skills Agility Learning-by-Doing Content 11

Harvard Business Review

AUGUST 3, 2012

Of course, this kind of talk is hardly encouraging to the scientists working for big pharma labs, and executive participants in our programs also shared with us their concerns that their best R&D talents are being depreciated and demotivated. As yet, the facts don't seem to substantiate the fears.

Licensing 12

Licensing Depreciation Pharmaceuticals Budgeting 12

Harvard Business Review

NOVEMBER 9, 2011

The answers may not be as self-evident as many executives think. Of the 97 largest listed companies in the UK and the Eurozone in 2010, only 37 had a COO in their executive ranks. Most COOs in Europe are seasoned executives; they were 48 years old, on average, when they were appointed.

COO 12

COO Sample Telecommunications Automotive 12

Harvard Business Review

OCTOBER 25, 2018

The superstars tend to be more involved in global flows of trade and finance, more digitally mature, and they dominate the lists of the most valued companies, the most valued brands, the most desirable places to work, and the most innovative companies.

Industry 12

Industry Company GDP Bottom-up 12

Harvard Business Review

AUGUST 6, 2015

I made a career switch seven years ago, when I went from working as a reporter at the Financial Times , where I covered health care in the United States, to consulting — advising CEOs in the pharmaceutical industry on thought leadership and articulating their corporate strategies. Execute fast. Consider the legal field.

Career 8

Career Skills Health Care Pharmaceuticals 8

Harvard Business Review

JUNE 16, 2016

Pharmaceutical companies spend millions upon millions preparing meticulous plans for new drug launches – and yet their route-to-market strategies haven’t changed in decades, even though the reality of the market has. The failure stemmed from resistance in the U.S. What builds management perspectives?

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

MARCH 14, 2017

In a recent Gallup poll , the pharmaceutical industry was the most widely disliked private industry, ranking even lower than lawyers. ” Meanwhile, the company recruited non-scientist talent from finance, consulting, tech, academia, and political campaigns and inserted them into drug-development roles.

Innovation 9

Innovation Company Incentives Industry 9

Harvard Business Review

SEPTEMBER 10, 2013

In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Executing on Innovation An HBR Insight Center. Finance Innovation' Five Ways to Innovate Faster.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Executing on Innovation An HBR Insight Center. Innovation Isn’t an Idea Problem. Ready to Innovate?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MAY 5, 2016

Senior executives should not lose perspective on the enormous opportunities in Iran, but they must be prepared to navigate some serious challenges. sanctions are delaying these projects being financed. Senior executives should be ready to trace the origins of and combat grey market trade and counterfeits of their products in Iran.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

MARCH 24, 2011

Among McKinsey's biggest clients in the 1990s were pharmaceuticals and financial-services companies. They paid their executives accordingly, as did the banks, brokerage houses, hedge funds, and private-equity outfits whose share of U.S Was it only ten years ago that the profits of the top 10 U.S. And what risks did he run?

McKinsey 14

McKinsey Consultative Waterman Intellectual Capital 14

Harvard Business Review

APRIL 23, 2012

Supreme Court is expected to rule on whether the work done by pharmaceutical salespeople really counts as "selling." pharmaceutical industry could face billions in retroactive overtime. By any reasonable definition, pharmaceutical salespeople are absolutely salespeople. SmithKline Beecham Corp. By June, the U.S. Analyze Needs.

Pharmaceuticals 13

Pharmaceuticals Banking Objective Incentives 13

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. Sometimes in IoT businesses, the answer is actually less tech and more traditional execution.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

SEPTEMBER 19, 2016

Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. In these cases, running the numbers and grasping what they tell you is important, but it isn’t enough. With gray area problems, you have to look hard at the economics and look past the economics. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8

Harvard Business Review

JANUARY 26, 2016

and European corporations, from CI-trained analysts in marketing, business development, strategy, R&D, finance, and other fields. First, many executives decide on a course of action and then use CI to ratify their choice. We received 236 responses from 21 industries in U.S. They had an average of 6.3

Competitive Intelligence 8

Competitive Intelligence Company CAPEX Analysis 8

Harvard Business Review

JUNE 20, 2017

Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards. Multinational executives are also paying attention to the country’s upcoming presidential elections.

Supply Chain 9

Supply Chain Depreciation Uncertainty Marketing 9

Harvard Business Review

JANUARY 4, 2017

There are similar stories in the electronics industry, pet food, pharmaceuticals, and even national security. This regulation came as a result of concerns that the exploitation and trade of conflict minerals by armed groups was helping to finance conflict in the DRC region and contributing to its emergency humanitarian crisis.

Supply Chain 9

Supply Chain Productivity Products Company 9